{"id":"NCT04029116","sponsor":"Scynexis, Inc.","briefTitle":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) Compared to Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-10-21","primaryCompletion":"2021-09-01","completion":"2021-11-29","firstPosted":"2019-07-23","resultsPosted":"2023-06-18","lastUpdate":"2023-06-18"},"enrollment":440,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Recurrent Vulvovaginal Candidiasis"],"interventions":[{"type":"DRUG","name":"Fluconazole Tablet","otherNames":[]},{"type":"DRUG","name":"IBREXAFUNGERP","otherNames":["SCY-078"]},{"type":"DRUG","name":"Placebo oral tablet","otherNames":[]}],"arms":[{"label":"Ibrexafungerp","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly \"SCY-078\") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).","primaryOutcome":{"measure":"Clinical Success","timeFrame":"Week 24","effectByArm":[{"arm":"Ibrexafungerp","deltaMin":85,"sd":null},{"arm":"Placebo","deltaMin":69,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":25,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":130},"commonTop":["Headache","Bacterial vaginosis","Diarrhoea","Nausea","COVID-19"]}}